Industry leaders supplying NHS with medicines condemn proposal for branded-medicines statutory scheme
Research and investment in UK life sciences will be harmed if the government continues with its proposals for the statutory scheme for the costing of branded medicines, industry leaders have warned.
More than 20 figures from major companies supplying the NHS with essential medicines branded the plans “unworkable” and called for the government to “take another look”.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.